Vanguard Growth ETFs Compared: Should You Go for Megacap or Small-Cap Growth Stocks to Finish Out 2026?

Vanguard’s two growth ETFs match on cost with a 0.05% expense ratio, but differ sharply by market-cap exposure: MGK is more tech-concentrated (72%) across 56 holdings, while VBK is broadly diversified (543 holdings) with tech at 23% and healthcare at 18.8%. Over the trailing year (as of 8/27/26), VBK leads on returns at 23.4% vs MGK’s 17.5%, though MGK shows higher total growth over five years ($1,882 vs $1,268 from $1,000). Risk is similar with max drawdowns over five years of -38.4% (VBK) vs -36.0% (MGK), suggesting modest differences in volatility but distinct concentration/upsides for portfolio construction.

Analysis

This is not a fundamentals catalyst so much as a positioning/flow read: low-cost growth wrappers keep compressing the decision between concentrated mega-cap duration and broader small-cap cyclicality. In a market still dominated by passive allocation, incremental demand will likely keep leaking toward the larger, liquid AI/platform names inside MGK because they are the default implementation vehicle for growth exposure; that supports AAPL/MSFT/NVDA more than it changes their earnings trajectory. VBK’s broader basket gives it more embedded leverage to a soft-landing breadth trade, but also more vulnerability to financing costs and earnings misses among lower-quality growers.

The key second-order effect is rate sensitivity. If real yields stay sticky, small-cap growth should underperform because valuation support matters more than narrative optionality; that favors MGK on a 1-3 month horizon. If the market starts pricing cuts and a wider cyclical rebound, VBK can catch up fast because its constituents have more operating leverage and less crowding, even if the index-level benefit is diluted across 543 names. That makes the relative trade highly regime-dependent rather than a clean directional call.

Contrarian view: the consensus may be over-indexing on the recent outperformance of mega-cap growth as if it were purely fundamental, when a meaningful slice is simply scarcity of earnings quality and liquidity. If breadth broadens, the market could reward the next tier of growth names faster than expected, especially in areas tied to tools, diagnostics, and network infrastructure such as CRDO, NTRA, and RVMD. What would falsify the MGK-vs-VBK bias is a sharp decline in real yields or a sustained rally in small-cap indexes over several weeks; that would argue the factor rotation has room to extend rather than fade.

Key Decisions for Investors

• Tactically long MGK / short VBK for the next 4-8 weeks if 10Y real yields remain above recent lows; thesis is that concentrated mega-cap earnings quality retains the bid while smaller growers stay discount-rate constrained. Risk/reward is about 1.5:1 if the growth factor stalls, but stop if VBK outperforms MGK by ~3-4% on a rolling month.
• If you want single-name exposure instead of ETF beta, use the article as a prompt to overweight NVDA/MSFT/AAPL on pullbacks rather than chase broader growth proxies; these names are the highest-conviction liquidity sinks if passive flows keep favoring the top of the cap stack.
• Set an alert on the 10Y real yield and IWM relative strength: if real yields fall and IWM leads for 2-3 weeks, rotate from MGK into VBK or a small-cap growth basket. That is the cleanest reversal trigger and would likely outperform the article’s implied mega-cap preference over a 1-3 month horizon.
• For a more balanced expression, pair long MGK with a partial short in a small-cap growth ETF proxy only if credit spreads widen; that isolates duration risk. If credit remains stable, the pair likely drifts and may not be worth the carry.
• No urgent action in RVMD/NTRA/CRDO from this note alone; treat them as watch-list beneficiaries of a breadth rotation. They become more attractive only if forward rates ease and small-cap growth multiple dispersion begins to compress.